Juliana Maira Watanabe Pinhata

Dr. Juliana Maira Watanabe Pinhata

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

25 October 2018 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
BLBeatriz Lopez
Beatriz Lopez
RORosangela Siqueira de Oliveira
Rosangela Siqueira de Oliveira
Juliana Maira Watanabe PinhataJuliana Maira Watanabe Pinhata
Juliana Maira Watanabe Pinhata
ECErica Chimara
Erica Chimara
EAEdson Pacheco Ascencio
Edson Pacheco Ascencio
AMAnandi Martin
Anandi Martin
To describe the distributions of bedaquiline and linezolid MIC values for the Mycobacterium tuberculosis WT population and to define the corresponding epidemiological cut-offs (ECOFFs) in three Latin American countries. MICs of bedaquiline and linezolid were determined by the resazurin microtitre assay (REMA). In phase 1, interlaboratory reproducibility was assessed using a panel of 10 fully susceptible M. tuberculosis strains. Phase 2 involved MIC determination for 248 clinical isolates from Argentina (n = 58), Brazil (n = 100) and Peru (n = 90) from patients who were treatment-naive for bedaquiline and linezolid. We then determined the ECOFFs for bedaquiline and linezolid by the eyeball method and the ECOFFinder statistical calculator. Phase 1: REMA MIC values in the three sites were either identical to each other or differed by one 2-fold dilution from the consensus value with the exception of a single value. Phase 2: the bedaquiline MIC range was 0.0039–0.25 mg/L for pan-susceptible and drug-resistant isolates combined. The linezolid MIC range was 0.062–0.5 mg/L for pan-susceptible isolates and 0.031–4 mg/L for drug-resistant isolates. ECOFFs were 0.125 mg/L for bedaquiline and 0.50 mg/L for linezolid. REMA is reproducible and robust for the determination of bedaquiline and linezolid MIC distributions and ECOFF values when applied in laboratories of medium/low-resource countries. We suggest that WT MIC distributions for both drugs should be used as a monitoring tool to control the possible rapid emergence of resistance.

1 March 2018 in Journal of Medical Microbiology
Verified
Journal Article
Closed access
MGMaria Cecília Gorla
Maria Cecília Gorla
ACAna Paula Cassiolato
Ana Paula Cassiolato
Juliana Maira Watanabe PinhataJuliana Maira Watanabe Pinhata
Juliana Maira Watanabe Pinhata
CMCamile de Moraes
Camile de Moraes
ACAlejandra Corso
Alejandra Corso
ALAna Paula Lemos
Ana Paula Lemos
To prevent secondary invasive meningococcal disease (IMD) cases and outbreaks, antimicrobial prophylaxis of high-risk contacts is indicated. This study reports two ciprofloxacin-resistant Neisseria meningitidis strains in Brazil. The 3523 N. meningitidis isolates collected throughout Brazil from 2009 to 2016 were evaluated for antimicrobial resistance. Meningococcal isolates showing minimal inhibitory concentrations, MICs≥0.125µg ml−1 to ciprofloxacin, were analysed to determine the presence of mutations in the quinolone resistance-determining regions (QRDRs) of gyrA and parC genes. Two ciprofloxacin-resistant N. meningitidis isolates were found, both presenting a single mutation in the quinolone resistance-determining region of the gyrA gene. These results confirmed that ciprofloxacin is still a first-line drug for chemoprophylaxis. However, we highlight the importance of continued surveillance to monitor the trends of N. meningitidis susceptibility profiles to the antimicrobials recommended for chemoprophylaxis and IMD treatment.

1 August 2018 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
JGJ.F. Gallo
J.F. Gallo
Juliana Maira Watanabe PinhataJuliana Maira Watanabe Pinhata
Juliana Maira Watanabe Pinhata
VSV. Simonsen
V. Simonsen
VGV.M.N. Galesi
V.M.N. Galesi
LFL. Ferrazoli
L. Ferrazoli
ROR.S. Oliveira
R.S. Oliveira

1 February 2017 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
AAAline Gois Adami
Aline Gois Adami
JGJuliana Failde Gallo
Juliana Failde Gallo
Juliana Maira Watanabe PinhataJuliana Maira Watanabe Pinhata
Juliana Maira Watanabe Pinhata
MMMaria Conceição Martins
Maria Conceição Martins
CGCarmen Maria Saraiva Giampaglia
Carmen Maria Saraiva Giampaglia
RORosangela Siqueira de Oliveira
Rosangela Siqueira de Oliveira

1 January 2020 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
TMTania Matsui
Tania Matsui
Juliana Maira Watanabe PinhataJuliana Maira Watanabe Pinhata
Juliana Maira Watanabe Pinhata
MRMichelle Christiane da Silva Rabello
Michelle Christiane da Silva Rabello
ABAngela Pires Brandão
Angela Pires Brandão
LFLucilaine Ferrazoli
Lucilaine Ferrazoli
RORosangela Siqueira de Oliveira
Rosangela Siqueira de Oliveira
In 2018, the World Health Organization (WHO) reported that there were an estimated 390,000 new cases of MDR-TB worldwide, with 548 new cases of TB with RIF resistance/MDR in Brazil alone.1,8 In 2017, the Ministry of Health of Brazil initiated the National Plan for the end of TB with the goal of reducing the 90% incidence and 95% mortality rates by 2035. One of the proposed strategies included molecular tests for drug resistance detection, which would allow for a more rapid diagnosis.9